Maryland reaches $340 million Conowingo Dam agreement with Constellation
Investing.com -- Eli Lilly (NYSE:LLY) plans to submit its experimental weight-loss pill orforglipron for regulatory approval across multiple major markets "within weeks" of each other, company’s international president Patrik Jonsson told Reuters.
"We are submitting to most of the major regulatory bodies pretty much at the same time," Jonsson said.
The pharmaceutical giant will file applications with regulators in the United States, Britain, European Union, Japan, and China in a coordinated approach, the report said.
Jonsson added that submissions would also be made to regulatory authorities in the United Arab Emirates and Saudi Arabia.
This synchronized global filing strategy appears designed to help Eli Lilly strengthen its position in the expanding weight-loss drug market, where it competes with Novo Nordisk.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.